Arcutis Biotherapeutics, Inc.
ARQT
Rangering i aksjer
#4024
Arcutis Biotherapeutics, Inc. is a biopharmaceutical firm dedicated to... Arcutis Biotherapeutics, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for a range of skin-related diseases. The company's flagship investigational compound, ARQ-151, a roflumilast cream administered topically, has successfully concluded late-stage clinical development for treating both plaque psoriasis and atopic dermatitis. Beyond its lead asset, Arcutis's pipeline includes several other promising compounds. Among these is ARQ-154, a roflumilast foam applied topically, aimed at seborrheic dermatitis and scalp psoriasis. Furthermore, ARQ-252, a topical selective Janus kinase type 1 (JAK1) inhibitor, is under investigation for hand eczema and vitiligo. ARQ-255, a variation of ARQ-252 designed for deeper dermal absorption, is being explored for alopecia areata. Established in 2016, the company was initially named Arcutis, Inc. before changing to Arcutis Biotherapeutics, Inc. in October 2019. Its corporate headquarters are situated in Westlake Village, California.
Aksjekurs
$31.91
Sist synkronisert: 2026-10-21
Markedsverdi
$4.01B
Endring (1 dag)
-2.77%
Endring (1 år)
61.08%
Land
US
Handel Arcutis Biotherapeutics, Inc. (ARQT)
Kategori
Healthcare
Aksjeprishistorikk for Arcutis Biotherapeutics, Inc. (ARQT)
Høyeste sluttskurs: $27.20 den 2026-10-01
Laveste sluttskurs: $21.80 den 2020-01-01
Laveste sluttskurs: $21.80 den 2020-01-01
Aksjeprishistorikk for Arcutis Biotherapeutics, Inc. fra 2020 til 2026
Årlig aksjeprisytelse
| År | Ytelse |
|---|---|
| 2026 (TTM) | -13.06% |
| 2025 | 117.39% |
| 2024 | 438.98% |
| 2023 | -84.13% |
| 2022 | -9.27% |
| 2021 | -38.74% |
| 2020 | 0.00% |
Aksjepris for lignende selskaper eller konkurrenter
| Selskap | Aksjepris | Endring 1år% | Land |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $758.21 | 7.77% |
CH
|
